Trilaciclib with chemotherapy for EGFR-mutant advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have EGFR-mutant NSCLC that has gotten worse after treatment with a third-generation EGFR TKI (like osimertinib).
- You are able to do most daily activities on your own (ECOG 0 or 1).
- Your cancer has at least one tumor that can be measured on a scan.
- You do not have serious heart, lung, or blood diseases, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
This study tests whether adding trilaciclib (a medicine given with chemotherapy) can improve outcomes for people with extensive-stage small cell lung cancer who are being treated with topotecan. It compares trilaciclib versus a placebo (inactive pill) while you receive topotecan.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.